Hemophilia interventional trial participants’ race and ethnicity according to trial characteristics
| . | No. of participants . | White N (%) . | Black N (%) . | Asian N (%) . | Other N (%) . | Unknown N (%) . | Multiple race N (%) . | AI/AN N (%) . | Hispanic N (%) . | P value∗ . |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase | <.001 | |||||||||
| 1 | 109 | 76 (69.7) | 2 (1.8) | 29 (26.6) | 1 (0.9) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | |
| 2 | 509 | 418 (82.1) | 27 (5.3) | 33 (6.5) | 21 (4.1) | 0 (0) | 1 (0.2) | 1 (0.2) | 18 (3.5) | |
| 3 | 3351 | 2300 (68.6) | 139 (4.1) | 694 (20.7) | 78 (2.3) | 95 (2.8) | 8 (0.2) | 23 (0.7) | 204 (6.1) | |
| 4 | 604 | 216 (35.8) | 11 (1.8) | 287 (47.5) | 6 (1.0) | 78 (12.9) | 1 (0.2) | 5 (0.8) | 11 (1.8) | |
| Completion year | <.001 | |||||||||
| 2007-2011 | 111 | 97 (87.4) | 1 (0.9) | 3 (2.7) | 5 (4.5) | 0 | 0 | 5 (4.5) | 19 (17.1) | |
| 2012-2016 | 895 | 608 (67.9) | 27 (3.0) | 160 (17.9) | 10 (1.1) | 80 (8.9) | 0 | 2 (0.2) | 29 (3.2) | |
| 2017-2022 | 3567 | 2305 (64.6) | 151 (4.2) | 880 (24.7) | 91 (2.6) | 93 (2.6) | 10 (0.3) | 23 (0.6) | 185 (5.2) | |
| Trial length | <.001 | |||||||||
| <2 y | 951 | 550 (57.8) | 34 (3.6) | 345 (36.3) | 4 (0.4) | 14 (1.5) | 0 (0) | 2 (0.2) | 62 (6.5) | |
| 2-5 y | 1733 | 1157 (66.8) | 67 (3.9) | 370 (21.7) | 65 (3.8) | 28 (1.6) | 8 (0.5) | 20 (1.2) | 96 (5.5) | |
| >5 y | 1889 | 1303 (69.0) | 78 (4.1) | 328 (17.4) | 37 (2.0) | 131 (6.9) | 2 (0.1) | 8 (0.4) | 75 (4.0) | |
| Sponsor type | <.001 | |||||||||
| Industry | 4500 | 2950 (65.6) | 178 (4.0) | 1041 (23.2) | 101 (2.2) | 173 (3.8) | 10 (0.2) | 25 (0.6) | 229 (5.1) | |
| Academic | 73 | 60 (82.2) | 1 (1.4) | 2 (2.7) | 5 (6.8) | 0 | 0 | 5 (6.8) | 4 (5.5) | |
| Hemophilia category | <.001 | |||||||||
| Hem A | 3318 | 2153 (64.9) | 119 (3.6) | 753 (22.7) | 81 (2.4) | 164 (4.9) | 5 (0.2) | 29 (0.9) | 198 (6.0) | |
| Hem B | 536 | 370 (69.0) | 26 (4.9) | 124 (23.1) | 5 (0.9) | 6 (1.) | 2 (0.4) | 0 (0) | 17 (3.2) | |
| Hem A and B | 719 | 487 (67.7) | 34 (4.7) | 166 (23.1) | 20 (2.8) | 3 (0.4) | 3 (0.4) | 1 (0.1) | 18 (2.5) | |
| Severity† | <.001 | |||||||||
| Severe | 3030 | 2025 (66.8) | 116 (3.8) | 691 (22.8) | 51 (1.7) | 118 (3.9) | 6 (0.2) | 9 (0.3) | 145 (4.8) | |
| Moderate and severe | 374 | 204 (54.5) | 2 (0.5) | 157 (42.0) | 0 (0) | 11 (2.9) | 0 (0) | 0 (0) | 0 (0) | |
| All severities | 306 | 196 (64.1) | 35 (11.4) | 52 (17.0) | 8 (2.6) | 11 (3.6) | 2 (0.7) | 1 (0.3) | 32 (10.5) | |
| Missing | 863 | 585 (67.8) | 26 (3.0) | 143 (16.6) | 47 (5.4) | 33 (3.8) | 2 (0.2) | 20 (2.3) | 56 (6.5) | |
| Included participants with inhibitor | <.001 | |||||||||
| No | 3490 | 2326 (66.6) | 95 (2.7) | 825 (23.6) | 62 (1.8) | 145 (4.2) | 7 (0.2) | 10 (0.3) | 138 (4.0) | |
| Yes | 1083 | 684 (63.2) | 84 (7.8) | 218 (20.1) | 44 (4.1) | 28 (2.6) | 3 (0.3) | 20 (1.8) | 95 (8.8) | |
| . | No. of participants . | White N (%) . | Black N (%) . | Asian N (%) . | Other N (%) . | Unknown N (%) . | Multiple race N (%) . | AI/AN N (%) . | Hispanic N (%) . | P value∗ . |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase | <.001 | |||||||||
| 1 | 109 | 76 (69.7) | 2 (1.8) | 29 (26.6) | 1 (0.9) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | |
| 2 | 509 | 418 (82.1) | 27 (5.3) | 33 (6.5) | 21 (4.1) | 0 (0) | 1 (0.2) | 1 (0.2) | 18 (3.5) | |
| 3 | 3351 | 2300 (68.6) | 139 (4.1) | 694 (20.7) | 78 (2.3) | 95 (2.8) | 8 (0.2) | 23 (0.7) | 204 (6.1) | |
| 4 | 604 | 216 (35.8) | 11 (1.8) | 287 (47.5) | 6 (1.0) | 78 (12.9) | 1 (0.2) | 5 (0.8) | 11 (1.8) | |
| Completion year | <.001 | |||||||||
| 2007-2011 | 111 | 97 (87.4) | 1 (0.9) | 3 (2.7) | 5 (4.5) | 0 | 0 | 5 (4.5) | 19 (17.1) | |
| 2012-2016 | 895 | 608 (67.9) | 27 (3.0) | 160 (17.9) | 10 (1.1) | 80 (8.9) | 0 | 2 (0.2) | 29 (3.2) | |
| 2017-2022 | 3567 | 2305 (64.6) | 151 (4.2) | 880 (24.7) | 91 (2.6) | 93 (2.6) | 10 (0.3) | 23 (0.6) | 185 (5.2) | |
| Trial length | <.001 | |||||||||
| <2 y | 951 | 550 (57.8) | 34 (3.6) | 345 (36.3) | 4 (0.4) | 14 (1.5) | 0 (0) | 2 (0.2) | 62 (6.5) | |
| 2-5 y | 1733 | 1157 (66.8) | 67 (3.9) | 370 (21.7) | 65 (3.8) | 28 (1.6) | 8 (0.5) | 20 (1.2) | 96 (5.5) | |
| >5 y | 1889 | 1303 (69.0) | 78 (4.1) | 328 (17.4) | 37 (2.0) | 131 (6.9) | 2 (0.1) | 8 (0.4) | 75 (4.0) | |
| Sponsor type | <.001 | |||||||||
| Industry | 4500 | 2950 (65.6) | 178 (4.0) | 1041 (23.2) | 101 (2.2) | 173 (3.8) | 10 (0.2) | 25 (0.6) | 229 (5.1) | |
| Academic | 73 | 60 (82.2) | 1 (1.4) | 2 (2.7) | 5 (6.8) | 0 | 0 | 5 (6.8) | 4 (5.5) | |
| Hemophilia category | <.001 | |||||||||
| Hem A | 3318 | 2153 (64.9) | 119 (3.6) | 753 (22.7) | 81 (2.4) | 164 (4.9) | 5 (0.2) | 29 (0.9) | 198 (6.0) | |
| Hem B | 536 | 370 (69.0) | 26 (4.9) | 124 (23.1) | 5 (0.9) | 6 (1.) | 2 (0.4) | 0 (0) | 17 (3.2) | |
| Hem A and B | 719 | 487 (67.7) | 34 (4.7) | 166 (23.1) | 20 (2.8) | 3 (0.4) | 3 (0.4) | 1 (0.1) | 18 (2.5) | |
| Severity† | <.001 | |||||||||
| Severe | 3030 | 2025 (66.8) | 116 (3.8) | 691 (22.8) | 51 (1.7) | 118 (3.9) | 6 (0.2) | 9 (0.3) | 145 (4.8) | |
| Moderate and severe | 374 | 204 (54.5) | 2 (0.5) | 157 (42.0) | 0 (0) | 11 (2.9) | 0 (0) | 0 (0) | 0 (0) | |
| All severities | 306 | 196 (64.1) | 35 (11.4) | 52 (17.0) | 8 (2.6) | 11 (3.6) | 2 (0.7) | 1 (0.3) | 32 (10.5) | |
| Missing | 863 | 585 (67.8) | 26 (3.0) | 143 (16.6) | 47 (5.4) | 33 (3.8) | 2 (0.2) | 20 (2.3) | 56 (6.5) | |
| Included participants with inhibitor | <.001 | |||||||||
| No | 3490 | 2326 (66.6) | 95 (2.7) | 825 (23.6) | 62 (1.8) | 145 (4.2) | 7 (0.2) | 10 (0.3) | 138 (4.0) | |
| Yes | 1083 | 684 (63.2) | 84 (7.8) | 218 (20.1) | 44 (4.1) | 28 (2.6) | 3 (0.3) | 20 (1.8) | 95 (8.8) | |
Number of trial participants across 66 trials that reported data on race and ethnicity.
Race is reported separately from ethnicity (non-Hispanic vs Hispanic), thus the sum of percentages across race and ethnicity will be ≥100.
AI/AN, American Indian/Alaska Native; Hem, hemophilia.
P values were computed with χ2 tests that compare differences in the racial distribution across trial characteristics.
There were no trials recorded as having only mild or mild and moderate participants.